Lutetium-177
As of the edition of 20 October 2026, Lutetium-177 is a drug known only by a code name: of no established status; acts on FOLH1, SSTR1 and SSTR2 and 3 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Status not established
- Kind
- Code name only
- Registered trials
- 1, 0 stopped early
- Disease areas
- Cancer; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Pfizer | Lead sponsor of trials | 2023 to now |